Y-mAbs Therapeutics, Inc. With a strong commitment to addressing unmet medical needs in both pediatric and adult populations, Y-mAbs aims to become the global leader in antibody-based oncology products. They offer a diverse and advanced product pipeline that includes pivotal-stage candidates targeting various types of cancer.

Y-mAbs focuses on rare and challenging pediatric cancers such as neuroblastoma, CNS/LM, osteosarcoma, DIPG, medulloblastoma, and DSRCT. Their research and development efforts revolve around developing cutting-edge immunotherapy platforms, radioimmunotherapy, and companion diagnostics. Driven by a strong sense of purpose, Y-mAbs also places great emphasis on patient and family support.

Founded by a father whose daughter survived a high-risk neuroblastoma, the company is driven by a mission to provide access to effective treatments and improve outcomes for cancer patients. With ongoing clinical trials and a commitment to collaboration, Y-mAbs is at the forefront of changing the landscape of cancer care. Learn more about their pioneering work and potential real-life possibilities